BioSpace News Archive

Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for the second quarter 2020 following the close of market on Thursday, August 6, 2020.

McKesson announced that The Disability Equality Index has named the company as one of its 2020 Best Places to Work for Disability Inclusion with a top-ranking score of 100.

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that it has dosed the first patient in VANGARD, a potentially pivotal Phase 2 clinical trial to evaluate PB1046 as a treatment for hospitalized COVID-19 patients who are at high risk for rapid clinical deterioration and acute respiratory distress syndrome (ARDS).

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced that it has granted a stock option to purchase 20,000 shares of common stock to one new employee.

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that its licensing partner Specialised Therapeutics Asia (STA) has received marketing approval of NERLYNX® (neratinib) in Malaysia from the Drug Control Agency (DCA), under Malaysia’s Ministry of Health (MOH).

ATW announces that it is unable to file its interim financial statements and accompanying management’s discussion and analysis, and related CEO and CFO certifications, for the period ended March 31, 2020 (the “Interim Filings”), by the filing deadline provided for under the temporary exemption granted under decision N°2020-PDG-0023

The U.S. Food and Drug Administration continued to take action in the ongoing response to the COVID-19 pandemic

Washington-based health systems, CHI Franciscan and Virginia Mason, along with CommonSpirit Health, the parent company of CHI Franciscan, announced today they have signed a Memorandum of Understanding (MOU) to explore combining the two health systems through a formation of a Joint Operating Company.

The CureScience™ Institute, a non-profit organization, focused on the acceleration of curative therapies for unmet needs, announced today a strategic expansion of its vision and mission.

ALX Oncology Holdings Inc. (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the pricing of its initial public offering of 8,500,000 shares of its common stock at a public offering price of $19.00 per share.